多血浆生物标志物用于射血分数保留的心力衰竭风险分层
本研究在TOPCAT试验的379例HFpEF患者中检测49种血浆生物标志物,并在PHFS队列156例中验证,发现多个新型生物标志物可预测全因死亡或心衰住院,机器学习多标志物模型显著改善风险预测。
要点
- 多种血浆生物标志物与HFpEF患者DHFA风险独立相关。
- 机器学习多标志物模型对DHFA有强预测价值,标准化HR 2.85。
- 该模型在独立队列中验证有效,且独立于MAGGIC评分。
核心结论
- 多种关键病理生理领域的新型循环生物标志物可预测HFpEF结局。
- 多标志物联合机器学习是增强HFpEF风险分层的有前景策略。
研究设计与样本
- 在TOPCAT试验参与者(n=379)中检测49种血浆生物标志物。
- 在PHFS独立队列(n=156)中验证多标志物预测模型。
主要发现
- 发现两个紧密相关的主要生物标志物簇,涉及纤维化/组织重塑、炎症、肾损伤/功能障碍和肝纤维化。
- 多个生物标志物预测DHFA,包括FGF-23、OPG、TNF-α、sTNFRI、IL-6、YKL-40、FABP-4、GDF-15、Ang-2、MMP-7、ST-2和NT-proBNP。
- 机器学习多标志物模型预测DHFA的标准化HR为2.85(95%CI 2.03-4.02,p<0.0001)。
- 在PHFS队列中,该模型预测DHFA的标准化HR为2.74(95%CI 1.93-3.90,p<0.0001),独立于MAGGIC评分。
临床怎么用
- 多标志物联合机器学习模型可用于HFpEF患者风险分层,辅助临床决策。
- 该模型在MAGGIC评分基础上可进一步改善风险预测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Better risk stratification strategies are needed to enhance clinical care and trial design in heart failure with preserved ejection fraction (HFpEF). OBJECTIVES: The purpose of this study was to assess the value of a targeted plasma multi-marker approach to enhance our phenotypic characterization and risk prediction in HFpEF. METHODS: In this study, the authors measured 49 plasma biomarkers from TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trial participants (n = 379) using a Multiplex assay. The relationship between biomarkers and the risk of all-cause death or heart failure-related hospital admission (DHFA) was assessed. A tree-based pipeline optimizer platform was used to generate a multimarker predictive model for DHFA. We validated the model in an independent cohort of HFpEF patients enrolled in the PHFS (Penn Heart Failure Study) (n = 156). RESULTS: Two large, tightly related dominant biomarker clusters were found, which included biomarkers of fibrosis/tissue remodeling, inflammation, renal injury/dysfunction, and liver fibrosis. Other clusters were composed of neurohormonal regulators of mineral metabolism, intermediary metabolism, and biomarkers of myocardial injury. Multiple biomarkers predicted incident DHFA, including 2 biomarkers related to mineral metabolism/calcification (fibroblast growth factor-23 and OPG [osteoprotegerin]), 3 inflammatory biomarkers (tumor necrosis factor-alpha, sTNFRI [soluble tumor necrosis factor-receptor I], and interleukin-6), YKL-40 (related to liver injury and inflammation), 2 biomarkers related to intermediary metabolism and adipocyte biology (fatty acid binding protein-4 and growth differentiation factor-15), angiopoietin-2 (related to angiogenesis), matrix metalloproteinase-7 (related to extracellular matrix turnover), ST-2, and N-terminal pro-B-type natriuretic peptide. A machine-learning-derived model using a combination of biomarkers was strongly predictive of the risk of DHFA (standardized hazard ratio: 2.85; 95% confidence interval: 2.03 to 4.02; p < 0.0001) and markedly improved the risk prediction when added to the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure Risk Score) risk score. In an independent cohort (PHFS), the model strongly predicted the risk of DHFA (standardized hazard ratio: 2.74; 95% confidence interval: 1.93 to 3.90; p < 0.0001), which was also independent of the MAGGIC risk score. CONCLUSIONS: Various novel circulating biomarkers in key pathophysiological domains are predictive of outcomes in HFpEF, and a multimarker approach coupled with machine-learning represents a promising strategy for enhancing risk stratification in HFpEF.
引用
- Chirinos JA, Orlenko A, Zhao L, et al. Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2020. PMID: 32192654. doi:10.1016/j.jacc.2019.12.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。